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Supervised Injectable Heroin:
A Clinical Perspective
He´roı¨ne par injection supervise´e : une perspective clinique
James Bell, FAChAM, MD1,2, Rob van der Waal, MRes1,2,
and John Strang, FRCPsych, PhD1,2
Abstract
Background: Six recent randomised control trials (RCTs) have suggested that supervised injectable heroin (SIH) can be
effective in patients who persist in street heroin use during methadone treatment. However, short-term randomised control
trials have limitations in assessing the effectiveness of treatments for addictive disorders, which are chronic and relapsing
disorders of motivation. These RCTs particularly fail to capture the process of the SIH treatment and the diversity of influence
and change over time.
Method: This narrative review is based on the analysis of published data. Conclusions are drawn from a process of reflection
informed by experience in delivering one of the published trials, subsequent experiences in varying the way SIH is delivered,
and through consideration of possible mechanisms of action of SIH.
Observations: Many long-term, socially marginalised and demoralised people who are addicted to heroin experience few
rewards from the stability afforded by methadone treatment. Supervised injected heroin is sufficiently reinforcing for many of
these individuals to attend daily and participate in highly structured treatment. With an adequate daily dose of supervised
methadone to avoid withdrawal dysphoria, occasional diamorphine injections—not necessarily twice daily, or even every
day—is enough to hold people in treatment. Participation was associated with reduced amounts of non-prescribed drug use, a
gradual change in self-image and attitude, and for some subjects, a movement towards social reintegration and eventual
withdrawal from SIH.
Conclusions: Prescribed heroin is sufficiently motivating to hold a proportion of recidivist addicts in long-term treatment.
Participation in structured treatment provides respite from compulsive drug use, and a proportion of subjects develop suf-
ficient rewards from social reintegration to successfully withdraw from treatment. Such change, when it occurs, is slow and
stuttering.
Abre´ge´
Contexte : Six essais randomise´s controˆle´s (ERC) re´cents sugge`rent que l’he´roı¨ne par injection supervise´e (HIS) peut eˆtre
efficace chez les patients qui persistent a` utiliser de l’he´roı¨ne de rue durant leur traitement a` la me´thadone. Toutefois, les ERC
a` court terme ont des limites en ce qui concerne l’e´valuation de l’efficacite´ des traitements pour les troubles de de´pendance,
qui sont des troubles de motivation chroniques et re´cidivants. Ces ERC e´chouent particulie`rement a` saisir le processus du
traitement HIS et la diversite´ de l’influence et du changement avec le temps.
Me´thode : Cette e´tude narrative est fonde´e sur l’analyse des donne´es publie´es. Les conclusions sont tire´es d’un processus de
re´flexion e´claire´ par l’expe´rience d’avoir applique´ un des essais, les expe´riences subse´quentes sur la variation de la fac¸on dont
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l’HIS est administre´e, et par l’examen des me´canismes d’action possibles de l’HIS.
Observations : Bon nombre d’he´roı¨nomanes a` long terme, socialement marginalise´s et de´moralise´s ne tirent que peu de
satisfaction de la stabilite´ offerte par le traitement a` la me´thadone. L’he´roı¨ne par injection supervise´e offre suffisamment de
renforcement a` ces personnes pour qu’elles participent chaque jour a` un traitement hautement structure´. Une dose
quotidienne ade´quate de me´thadone supervise´e pour e´viter la dysphorie du sevrage, des injections occasionnelles de
diamorphine – pas ne´cessairement deux fois par jour, pas meˆme chaque jour – ont suffi a` garder ces personnes en
traitement. La participation e´tait associe´e a` une re´duction de l’utilisation de me´dicaments non prescrits, a` un changement
graduel de l’image de soi et de l’attitude, et pour certains patients, a` des de´marches vers une re´insertion sociale et un
sevrage e´ventuel de l’HIS.
Conclusion : L’he´roı¨ne prescrite est suffisamment motivante pour garder une proportion de toxicomanes re´cidivistes en
traitement a` long terme. La participation au traitement structure´ procure un re´pit a` l’utilisation compulsive de drogue, et une
proportion des sujets de´veloppent des avantages suffisants de la re´insertion sociale pour re´ussir a` se sevrer du traitement. Un
tel changement, quand il se produit, est lent et he´sitant.
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Introduction
Following the rapid rise in heroin addiction in manyWestern
countries in the 1990s, there was renewed interest in pre-
scribing diamorphine (pharmaceutical heroin) as a way to
ameliorate the devastating effects of heroin addiction. Ran-
domised controlled trials (RCTs) comparing the effective-
ness of Supervised Injectable Heroin (SIH) to oral
methadone were undertaken in Switzerland,1 the Nether-
lands,2 Spain,3 Germany,4,5 the UK6 and Canada.7 A meta-
analysis of the 6 RCTs concluded that, among people who
had failed to respond to methadone treatment, SIH was more
effective than methadone in suppressing street heroin use.8
In general, these positive findings have not persuaded
policy makers to support many existing programs or roll-
out the treatment more widely.9 This is not surprising. The
finding that people prescribed high-dose pharmaceutical her-
oin used less street heroin is not a strong argument that
treatment is effective (or even that SIH is ‘‘treatment’’ at
all). Most observers would require improvements in health,
quality of life, and social reintegration to accept that a treat-
ment is worthwhile. However, in comparing SIH with oral
methadone treatment, it is not possible to blind either parti-
cipants or staff to the treatment allocation, and self-reported
mood, quality of life and social functioning are susceptible to
bias, compromising the value of self-report. Even before the
RCTs were conducted, it was assumed that prescribing SIH
is motivational, attracting participation by offering access to
their drug of choice, and it was anticipated that subjects
randomised to the control group might be more likely to drop
out or experience resentful demoralisation, which would
make meaningful evaluation difficult.10
This was confirmed in some of the RCTs. For example, in
the German trial, 31% of control subjects dropped out early,
compared with 2% of those randomised to SIH; thereafter,
retention was almost identical in the 2 groups (p57).4 In
addition, the greatest self-reported improvements on the
Global Severity Index of the SCL-90 occurred while subjects
awaited group allocation and receipt of the first dose of
medication (p80).4 Clearly, such an improvement cannot
be attributed to the effects of heroin as medication.
Retention data from the German trial suggest that, in
addition to subject disappointment, staff attitudes may have
been another source of bias. Retention in the heroin arm was
broadly comparable across 6 locations in the German study,
ranging from 59% to 85% (mean, 67%) retained at 12
months. However, methadone retention differed widely,
from 21% retained in one centre to more than 80% in
another. The investigators commented that one clinic ‘‘man-
aged to maintain the attractiveness of methadone treatment’’
(p58).4 Treatment works better when staff believe in it,11 and
it is possible that staff in some centres were enthusiastic
about diamorphine treatment and felt that subjects in the
control condition had missed out, and this may have con-
tributed to the higher drop-out rates. These findings support
the suggestion that rules of evidence designed to test the
effectiveness of medications may be inappropriate when
assessing complex interventions for the motivational disor-
der of addiction.12
Recent research on psychological and self-help
approaches to addiction have moved from searching for evi-
dence that interventions ‘‘work’’ to asking questions of the
mechanisms by which they contribute to change, and for
which individuals and in what contexts different treatments
can be helpful.13,14 This more nuanced approach seems bet-
ter suited to assessing SIH as a form of treatment than is
undertaking clinical trials comparing SIH to a treatment
known to have previously failed in the target population.
This paper is based on our experience of delivering SIH,
first as a research trial, and then for several years as a clinical
service. The paper explores the mechanisms of action of
SIH, and proposes that the reported evidence from RCTs,
showing better results from SIH than from oral methadone,
may actually understate the effectiveness of this modality of
treatment for many participants. The paper reviews aspects
of the clinical trials that shed light on how prescribed heroin
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works, and uses clinical experience to suggest how super-
vised injectable heroin can contribute to recovery from
addiction.
Evidence from Published Trials
Did Prescribed Injectable Heroin Attract and Retain in Treatment
Otherwise Hard to Engage Heroin Users?. Despite confirmation
that participants who enrolled in the trials were seeking dia-
morphine, and tended to drop out if randomised to metha-
done, SIH trials struggled to attract participants into
treatment. Far from being a ‘‘honey pot’’ to draw in people
who wanted heroin, the Swiss, German, Spanish, the UK and
North American trials all reported recruitment problems, and
needed to extend the period of recruitment and (or) failed to
reach target numbers. Likewise, SIH trials failed to attract
new, previously ‘‘unreached’’ people to treatment; in the
German study, one arm of the trial set out to recruit people
not currently in treatment, but only 3% of recruits had no
prior treatment history.4
Did SIH Reduce the Use of Non-prescribed Drugs?. Attracting
and retaining participation in treatment is not in itself a
positive outcome;10 at best, retention is a proxy measure of
outcome. The critical outcome is a reduction in the use of
non-prescribed drugs, as reduction in street drug use is gen-
erally a prerequisite to improving physical and mental health
and restoring impaired social role.15 Evidence from all clin-
ical trials was consistent: prescribed, high-dose pharmaceu-
tical heroin helped subjects reduce or cease their use of street
heroin.8 However, the results of the 6 RCTs found little
difference in cocaine and other street drug use between SIH
and control subjects. Such drug use compromises the effec-
tiveness of treatment in promoting social reintegration.
Does SIH Facilitate Social Integration?.Waldorf and Biernacki16
refer to the ‘inter-world’ inhabited by a heroin user in treat-
ment as no longer part of the drug scene but not part of
mainstream society either. Many SIH subjects fit that
description, ceasing illicit use but not finding any social role
or affiliation. In part, this reflects a wider social problem in
the UK, and probably in any high income country with a
welfare system—the emergence of a long-term unemployed
underclass that is supported by welfare but impoverished,
demoralised, and often lacking a social role. Achieving sta-
ble housing, re-establishing relationships with family, and
re-entry into the workforce are changes that contribute to
the slow process of consolidation of a non-addict identity.
In all trials, there was little evidence of improved social
functioning in SIH subjects compared with controls.
However, clinical trials may underestimate the potential
effectiveness of SIH. During the trials, subjects on SIH and
those on methadone received the same psychosocial support
(or, in the case of the German trial, were randomly allocated
to 1 of 2 structured programs of psychosocial support). Dur-
ing the trial phase, case workers did not use the motivational
salience of SIH to steer subjects away from other drugs. In
our clinic, outside of the trial context, we began informing
patients that ongoing receipt of SIH was contingent on ceas-
ing benzodiazepine and cocaine use. Some patients were
prescribed reducing dosages of benzodiazepine to withdraw
safely. Our perception is that the motivational salience of
access to prescribed heroin was enough for many patients to
cease benzodiazepine and cocaine use, something not tested
in the clinical trials.
The Evolution of SIH in the London Clinic
Structured Treatment. SIH is a highly structured treatment,
and it became increasingly structured over time at the South
London clinic. The basic behavioural structure was daily
attendance and ritualised administration. During SIH, and
for the first months of treatment, patients attended twice
daily, 7 days per week. On arrival at the clinic, patients
checked in with the receptionist, then sat in the waiting
room until called through individually for their dosages.
On entering the injecting room, they identified themselves
to the 2 nurses, who would verify their identity and visually
confirm that the patient was not intoxicated. Nurses drew
up the prescribed dose of heroin, while patients washed
their hands thoroughly, then swabbed down the proposed
injecting site. Nurses then passed the loaded syringe to the
patient to inject themselves. Following injection, patients
then disposed of the used equipment, swabbed down all
surfaces, and spoke briefly with nurses to confirm that they
were not intoxicated. Once daily, patients were given a
dose of oral methadone, taken under observation. Patients
then left the clinic. Urine toxicology was performed about
fortnightly, on a day chosen at random.
Table. Timeline of SIH in the UK
 October 2005 – Opening of the 7-day-a-week SIH clinic for
the RIOTT trial (funding from Big Lottery, DH, and Home
Office);
 2007 – Policy evolves and decides that groin-injecting is not
permitted
 2006 – Darlington (northern England) SIH clinic
commissioned
 2007 – Brighton (southern England) SIH clinic commissioned
 2008 – Policy evolution – no benzodiazepine use
 2009 – End of RIOTT trial; public conference (organised by
Action on Addiction) about the experience and
observations of SIH and the RIOTT trial. Clinic funding
continued by DH
 2009 – Policy evolution: All methadone to be taken on site
 2011/12 – DH publicly calls for bids to provide
demonstration SIH clinics. All 3 clinics continue
 2014 – Satellite clinics (injecting up to 5 days per week)
opened in London for selected patients
 2015 – End of funding, forced closure of the all 3 UK
demonstration SIH clinics
DH, Department of Health; RIOTT, Randomised Injectable Opiate Treat-
ment Trial;6 SIH, supervised injectable heroin.
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Clinic policies, designed and progressively revised to
minimize risks, formed the core of the structure. Our obser-
vation was that patients misusing benzodiazepines or alcohol
were at increased risk of post-injection hypoxia. They also
tended to be more behaviourally chaotic. In patients known
to misuse alcohol, a breathalyser was used to confirm that
breath alcohol was at an acceptable level prior to receiving
heroin. Mortality is increased when benzodiazepines are co-
prescribed with opioid substitution treatment17 or with
opioid analgesics,18 and, over time, the clinic adopted a
‘‘no benzodiazepine’’ policy. Patients who appeared intoxi-
cated would have an on-the-spot urine dipstick test prior to
dosing. If they tested positive for benzodiazepines, no inject-
able drugs would be dispensed, and people would receive
oral methadone only on that day.
Rules around injecting were developed to minimize vein
damage. Patients were allowed a maximum of 3 attempts to
find a vein, and were discouraged from ‘‘digging’’ to find IV
access. Groin injecting was not permitted.19 In practice, most
patients moved to injecting intramuscularly. The result was
marked improvement in injecting-related abscesses and
ulcers, which were common at the initiation of SIH.
The cognitive component of the structure included clear
objectives of treatment: reduction and cessation of non-
prescribed drug use, attention to physical and mental
health, and assistance to promote social reintegration (such
as obtaining stable housing, participating in training
courses). Patients had fortnightly clinical reviews with key
workers, and medical reviews every 3 months or more fre-
quently if there were issues of medical or psychiatric
comorbidity.
The Impact of Structure
As noted above, recruitment difficulties were seen in all
published trials of SIH, and this emphasizes an important
aspect of diamorphine treatment—the ambivalence heroin
addicts feel toward structured treatment. From our experience
in the South London clinic, most patients missed 2 to 3
appointments before eventually presenting. Before joining the
SIH program, most people seeking SIH were homeless,
received low doses of methadone, and attended treatment
erratically. People with few social supports or without a
meaningful social role or identity other than ‘‘addict’’ often
saw little meaning in the concept of ‘‘recovery’’ and found
little appeal in treatment.20 Many at presentation were ‘‘hope-
less’’—without hope or expectation that life could be differ-
ent. Several patients presented in the anticipation of ‘‘free
heroin’’; their continued access to heroin was sufficient moti-
vation to attend and comply with clinic requirements.
Transition in identity and outlook is central to recovery
from drug dependence—a process characterized by Marie
Nyswander as the transition ‘‘from drug addict to patient’’.
The rituals of daily attendance, compliance with clinic rules
about hand washing and vein care, post-injection monitor-
ing, regular urine toxicology, and frequent clinical review;
these elements contributed to making heroin injecting a
‘treatment’ rather than access to free drugs. Diamorphine
is enough incentive for some people who are dependent on
heroin to accept rules and structure. Our observation was
that for most (not all) patients, participation in treatment
was associated with a gradual change in outlook, atten-
dance and presentation.
Doses. Because of the short half-life of heroin and its active
metabolites, subjects in the SIH trials were also provided
with oral methadone to avoid the emergence of withdrawal.
In the South London clinic, during the RCT, methadone
doses were moderate (40 to 60 mg) and were given to take
home and consume in the evenings to avoid withdrawal
overnight. However, in the post-trial phase of treatment,
which ran for 6 years, we experimented with approaches to
medication. The critical change was switching from provid-
ing methadone to take home, to giving all methadone as
supervised, on-site doses.
From the time this policy was introduced, there were no
further instances of post-injection respiratory depression
requiring intervention over the next 6 years. We assumed
that people had sought to increase the effect of diamorphine
by omitting all or part of their methadone, keeping tolerance
low to experience a greater effect from diamorphine. Fol-
lowing that observation, we implemented a policy of
increasing methadone dosages, so that everyone was taking
at least 60 mg/day in addition to diamorphine. The intention
was to minimize withdrawal dysphoria. Monitoring con-
firmed that patients on high-dose methadone and diamor-
phine still experienced a prompt physiological response to
the intramuscular injection of heroin, and that tolerance
induced by methadone was partial rather than complete.21
Frequency of Injecting. With an adequate dose of supervised
methadone to avoid withdrawal, the role of prescribed heroin
was to provide intermittent reward, and this did not always
need to be daily. Once stabilised on high-dose heroin—typi-
cally, 200 mg twice daily, along with 80 to 100 mg oral
methadone—and no longer using street heroin, many
patients were happy to reduce the frequency of injecting and
reduce the heroin dosage. Several patients initiated the
reduction in dosage and frequency within a few months,
mostly to free themselves from the requirement to attend the
clinic twice daily. Many patients dropped rapidly to 100 mg
heroin once daily, sometimes to 100 mg thrice weekly.
Use of Long-acting Medications other than Methadone. Some
patients were recruited on the grounds that they were
non-responders to methadone. We explored the use of
slow-release oral morphine as an alternative. A report of
patient responses has been published.22 A few patients on
buprenorphine were also commenced on injectable drugs.
They reported a gratifying effect of injecting diamorphine
but had poor control of withdrawal when the diamorphine
injections wore off, and all were eventually transferred to
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methadone. For patients on buprenorphine, injectable
buprenorphine may warrant consideration in those continu-
ing to inject street drugs.
Summary
Until the 1970s in the UK, prescribing heroin was the most
common approach for the treatment of heroin addiction. The
rationale for such prescribing was straightforward—it was a
humane response to people who found themselves in a pre-
dicament. There remains a common assumption that if her-
oin is wanted, prescribing it under controlled conditions, as a
stable dosage, can minimize the damage done by addiction.
To the extent that the problems of people addicted to
heroin are merely their addiction to heroin, providing a sta-
ble supply may well be the main function of prescribing
opioids—whether diamorphine, methadone or buprenor-
phine—to manage addiction. On occasion, there are individ-
uals who remain high-functioning and socially integrated
while maintained on prescribed IV heroin without supervi-
sion.23 However, the challenge facing communities is not the
few high-functioning addicts but the larger cohort of demor-
alised and socially marginalised heroin users who see little
benefit in the stability offered by conventional treatments.
Recent trials of SIH have targeted these ‘‘hard to reach’’
people: those who are less able to take advantage of the
respite from addiction offered by methadone or drug-free
treatment. SIH offers these people enough reinforcement to
participate in structured treatment. It requires skilled and
supported staff, a treatment ethos that focuses on supporting
social reintegration.
Structured treatment was necessary to minimize the risks
of overdose and diversion; however, it probably also has a
therapeutic element. Redefining heroin as medication—
ritually administered with an emphasis on safety and
hygiene—promoted a change in identity and outlook. Indi-
rect evidence from the RCTs suggest the importance of
structure, because participating generally had a beneficial
effect, regardless of the group to which subjects were allo-
cated. For example, in the Swiss RCT, more than half the
‘‘methadone non-responders’’ initially randomised to oral
methadone did well and declined the option of transferring
to diamorphine when the 6 months of randomised treatment
was completed;1 methadone non-responders had become
methadone responders. Highly structured treatment and
monitoring provided in RCTs may explain why methadone
became more effective in this previously refractory group.
Structured methadone treatment produces better out-
comes than unstructured treatment.24 If methadone were
delivered in small, well-staffed clinics rather than low-
cost, industrial-scale dispensing operations, an uncertain
number of ‘‘methadone treatment non-responders’’ might
become methadone responders. However, this does not mean
there is no place for SIH. There will continue to be people
who fail to respond to methadone treatment, and the evi-
dence from RCTs is sufficient: SIH is more effective than
optimised methadone treatment for people persisting in her-
oin use despite treatment. Our hypothesis is that SIH is
effective because heroin is one of the few things able to
motivate some individuals who have experienced long-
term and demoralising social exclusion.
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